

SUSPECT ADVERSE REACTION REPORT	
GT-TOLMAR, INC.-24GT046878	

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) CAML	1a. COUNTRY GUATEMALA	2. DATE OF BIRTH Day: 26, Month: May, Year: 1947	2a. AGE Years: 76	3. SEX Male	4-6 REACTION ONSET Day: , Month: Feb, Year: 2024	8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION <input type="checkbox"/> RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY <input type="checkbox"/> CONGENITAL ANOMALY <input checked="" type="checkbox"/> OTHER MEDICALLY IMPORTANT CONDITION
7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) 1) PAIN IN THE SPINE IS CAUSED BY THE PROSTATE CANCER BECAUSE IT METASTASISED IN THE AREA OF THE SPINE (Metastases to spine (10027468), Metastases to spine (10027468)) Not Recovered/Not Resolved/Ongoing 2) IN THE DAYS PRIOR, HE ALREADY HAD FLU-LIKE SYMPTOMS (Flu (10016790), Influenza (10022000)) (/Feb/2024 -) - Unknown 3) HEADACHE (Headache (10019211), Headache (10019211)) (10/Feb/2024 -) - Recovered/Resolved 4) CHILLS (Chills (10008531), Chills (10008531)) (/Mar/2024 -) - Not Recovered/Not Resolved/Ongoing						

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S)(include generic name) 1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (22.5 Milligram, Injection)(Unknown)	Cont..
15. DAILY DOSE(S) 1) (22.5 milligram(s), 1 in 3 Month)	Cont..
16. ROUTE(S) OF ADMINISTRATION 1) Subcutaneous	Cont..
17. INDICATION(S) FOR USE 1) Prostate cancer [10060862 - Prostate cancer]	Cont..
18. THERAPY DATE(S) (from/to) (09-Feb-2024 -)	19. THERAPY DURATION
20. DID EVENT ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA	
21. DID EVENT REAPPEAR AFTER REINTRODUCTION <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA (NA : Not Applicable)	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 1) Radiotherapy	Cont..
23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) 1) HEART PROBLEMS (10019277, Heart disorder) (//2008 -)	Cont..

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER Name : Tolmar, Inc 701 Centre Avenue Fort Collins, CO, 80526, UNITED STATES OF AMERICA debbie.maierhofer@tolmar.comand+1-4129158447	Study Information Study Name: NA EudraCT Number: Protocol No.: NA Center No.: Subject Id :
24. REPORT NULLIFIED <input type="checkbox"/> YES <input type="checkbox"/> NO	24b. MFR CONTROL NO. GT-TOLMAR, INC.-24GT046878
24c. DATE RECEIVED BY MANUFACTURER 28/May/2025	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL
DATE OF THIS REPORT 07/Jun/2025	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

5) CAUSES SPASMS (Abdominal spasm (10051889), Abdominal rigidity (10000090)(08/Mar/2024 -) - Recovering/Resolving)

6) HE HAS BEEN EXPERIENCING BURNING IN THE STOMACH, MENTIONING THAT HE CANNOT DIGEST ANYTHING (Dyspepsia (10013946), Dyspepsia (10013946)(08/Mar/2024 -) - Recovering/Resolving)

7) Cessation of therapy by the patient (Therapy cessation by patient (10072907), Therapy cessation (10065154) - Unknown)

8) Excessive sweating (Excess sweating (10015590), Hyperhidrosis (10020642)(/Feb/2025 -) - Not Recovered/Not Resolved/Ongoing)

9) Intense hot flashes (Hot flashes (10020407), Hot flush (10060800)(/Feb/2025 -) - Not Recovered/Not Resolved/Ongoing)

10) PAIN IN THE LOWER LIMBS (Pain in limb (10033447), Pain in extremity (10033425)(10/Feb/2024 -) - Recovered/Resolved)

Event Description :

This Study report from GUATEMALA was received by Adium (reference number: GT-ADIUM-GT-0086-20240212) on 12-FEB-2024 from a Consumer regarding an Elderly 76 Years old Male patient who experienced In the days prior, he already had flu-like symptoms (Flu), Headache (Headache), Pain in the lower limbs (Pain in limb), during Eligard (Leuprolide acetate) 22.5 milligram therapy for Prostate cancer. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 13-FEB-2024.

The patient's medical history and current conditions included Prostate cancer.

Concomitant medications were not reported.

On 09-FEB-2024, the patient began receiving Eligard 22.5 milligram, q 3 month via Subcutaneous use for Prostate cancer (Lot numbers and Expiration dates were not provided). On 10-FEB-2024, 2 days after the most recent dose of Eligard, the patient experienced significant pain in the lower limbs, as well as a headache, in the days prior, he already had flu-like symptoms. It was reported that the patient was feeling better, he was taking acetaminophen 1 g every 6 hours. No further details were provided.

Corrective treatment included ACETAMINOPHEN.

Action taken with Eligard in response to the events was unknown. De-challenge was not applicable, and re-challenge was not applicable.

The outcome of Flu was Unknown. The outcome of Headache was Recovered. The outcome of Pain in limb was Recovered.

The reporter did not assess the seriousness or causality of the events in relationship to Eligard and Eligard unspecified device.

On 13-MAR-2024, follow-up information was received from GUATEMALA by Adium via Patient Support Program "ASOFARMA A TU LADO" (reference number: GT-ADIUM-GT-0086-20240212) from a Consumer/Other Non-Health Prof and sent to Tolmar on 14-MAR-2024. New information included: New events of he has been experiencing burning in the stomach (Dyspepsia) and Causes spasms (Abdominal spasm). Radiotherapy added as concomitant, Bicalutamide added as concomitant.

Concomitant medications included: RADIOTHERAPY, BICALUTAMIDE.

On 08-MAR-2024, 1 month after the most recent dose of Eligard, the patient had been experiencing burning in the stomach, mentioning that he cannot digest anything as it caused spasms and burning in the stomach. Additionally, he mentioned that he underwent radiation therapy last week. The patient was asked if he had been taking any gastric protectants, and he reported that he had not taken any, so it was suggested that he consult with his treating physician. The patient reported feeling better and that he had been able to eat better.

Corrective treatment was not reported.

Action taken with Eligard in response to the events was unknown. De-challenge and re-challenge were not applicable.

The outcome of Abdominal spasm was Recovering. The outcome of Dyspepsia was Recovering.

The reporter did not assess the seriousness of the events and assessed the causality in relationship to Eligard and Eligard unspecified device as Not Reported.

On 23-MAY-2024, follow-up information was received from GUATEMALA by Adium (reference number: GT-ADIUM-GT-0086-20240212) from a Consumer and sent to Tolmar on 24-MAY-2024. New information included: new medically significant serious event of "Pain in the spine is caused by the prostate cancer because it metastasised in the area of the spine (Metastases to spine)", new non-serious event of "Chills (Chills)", updated clinical details.

The patient's medical history and current conditions included Prostate cancer and Heart disorder.

On 19-MAR-2024, the patient was prescribed Bicalutamide, 1 capsule per day, for prostate cancer.

Continuation Sheet for CIOMS report

On an unspecified date in MAR-2024, reported as for the last 2 months, unknown time after the most recent dose of Eligard, the patient experienced Chills.

On an unspecified date in MAY-2024, reported as for the last 15 days, unknown time after the most recent dose of Eligard, the patient experienced permanent pain in his spine.

On 20-MAY-2024, he went for a consultation with the treating doctor who told the patient that the chills were caused by the Eligard medication and the pain in the spine was caused by the prostate cancer because it metastasized in the area of the spine, which was causing pain.

The treating doctor prescribed the drugs Tramacet for spinal pain, Xtandi (Enzalutamide) and Prolia (denosumab) for spinal cancer.

Reportedly, before starting Eligard treatment in JAN-2024, the patient had a total prostate antigen test and the results showed 900 ng/ml, so the doctor prescribed the Eligard drug.

On 17-MAY-2024, the total prostate antigen test was carried out and the results were 0 ng/ml, so the doctor told the patient that thanks to the Eligard drug he had made great progress.

On 23-MAY-2024 the patient was given the Eligard 45 mg drug and not the 22.5 mg drug that was given in the first dose.

On 23-MAY-2024, the patient began receiving Eligard 45 milligram, q 6 month via Subcutaneous use for Prostate cancer (Lot numbers: 14177A1; Expiration dates: JUL-2025).

Corrective treatment included Tramacet [paracetamol; tramadol hydrochloride], Xtandi and Prolia.

Action taken with Eligard 22.5 mg in response to the events was Unknown. De-challenge was not applicable, and re-challenge was not applicable.

The outcome of Metastases to spine was Not Recovered. The outcome of Chills was Not Recovered.

Relevant test results included:

JAN-2024: Prostatic specific antigen 900 nanogram per milliliter (Ref range: Not provided)

17-MAY-2024: Prostatic specific antigen 0 nanogram per milliliter (Ref range: Not provided)

The reporter did not assess the seriousness or causality of Metastases to spine and Chills in relationship to Eligard and Eligard unspecified device.

On 28-May-2025, follow up information was received by Adium (reference number: GT-ADIUM-GT-0086-20240212 (3)). New information included: Added new non serious event of 'excessive sweating' (hyperhidrosis), 'intense hot flashes and excessive sweating, so by his own decision he discontinues treatment' (hot flush) and 'cessation of therapy by the patient' (therapy cessation). Updated Eligard 45 mg in case.

On 23-May-2024, the patient began receiving Eligard 45 milligram, every 6 months via subcutaneous use for prostate cancer (Lot numbers: 14177A1; UNK; UNK and expiration dates: JUL-2025).

On an unknown date, in Feb-2025, the patient experienced intense hot flashes and excessive sweating, so patient discontinues his treatment. No further details were provided.

Action taken with Eligard 22.5 and 45 mg in response to events was unknown. De-challenge was not applicable, and re-challenge was not applicable.

The outcome of event hyperhidrosis and hot flush was not resolved.

The outcome of therapy cessation was unknown.

The reporter did not assess the seriousness of event therapy cessation, hyperhidrosis and hot flush.

The reporter did not provide the causality of therapy cessation, hyperhidrosis and hot flush in relationship to Eligard 45 mg, Eligard 22.5 mg and Eligard Unspecified Device.

No further information was expected as the reporter did not consent to be contacted for follow up.

Listedness

Listedness of the events metastases to spine, influenza, headache, pain in extremity, chills, abdominal rigidity and dyspepsia is retained as per previous assessment.

Hyperhidrosis>Eligard>Listed as per CCDS>07-Nov-2024

Hyperhidrosis>Eligard>Listed as per USPI>Feb-2025

Hyperhidrosis>Eligard unspecified device>Listed as per USPI>Feb-2025

Hyperhidrosis>Eligard>Listed as per Canadian monograph>02-Apr-2025

Continuation Sheet for CIOMS report

Hot flush>Eligard>Listed as per CCDS>07-Nov-2024
 Hot flush>Eligard>Listed as per USPI>Feb-2025
 Hot flush>Eligard unspecified device>Listed as per USPI>Feb-2025
 Hot flush>Eligard>Listed as per Canadian monograph>02-Apr-2025

Therapy cessation>Eligard>Unlisted as per CCDS>07-Nov-2024
 Therapy cessation>Eligard>Unlisted as per USPI>Feb-2025
 Therapy cessation>Eligard unspecified device>Unlisted as per USPI>Feb-2025
 Therapy cessation>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Company Remarks (Sender's Comments) :

Evaluator Comment (Tolmar): This 76 years old male patient had Metastases to spine (Pain in the spine is caused by the prostate cancer because it metastasised in the area of the spine), Influenza (In the days prior, he already had flu-like symptoms), Abdominal rigidity (Causes spasms), Chills (Chills), Headache (Headache), Dyspepsia (He has been experiencing burning in the stomach, mentioning that he cannot digest anything) and Pain in extremity (Pain in the lower limbs) during Eligard (Leuprolide acetate) 22.5 milligram therapy for Prostate cancer. Tolmar assessed Metastases to spine as medically significant based on its nature and the remaining events as non-serious since there was no immediate jeopardy to patient and they did not meet ICH seriousness criteria. All events were assessed as not related to Eligard (drug and device) based on the etio-pathology of the events, known safety profile of the drug and inconsistency with drug properties and presence of alternate explanation. Metastases to spine was attributed to the underlying cancer as patients with malignancy have an increased predilection to develop distant cancer. Concomitant use of BICALUTAMIDE, denosumab and Xtandi confounds events chills, headache and dyspepsia. Use of radiotherapy and concomitant use of pain medications was an additional confounder for Abdominal rigidity and Dyspepsia. Metastases to spine could be contributory to pain in extremity.

FU-events hyperhidrosis (Excessive sweating), hot flush (Intense hot flashes) and therapy cessation (Cessation of therapy by the patient) were added. Tolmar assessed the event as non-serious since it does not meet the ICH seriousness criteria and is not an IME event. The reported event therapy cessation was assessed as not related to Eligard (drug and device) as the event occurred with the product due to human action, rather due to the drug. Events hyperhidrosis and hot flush were assessed as related to Eligard(drug) 45mg with the known safety profile of drug and assessed as not related to device component of Eligard.

Additional Information (Continuation...)

Lab Result :

Test Name	Test Date	Test Result	Normal Value
PROSTATE ANTIGEN TEST	/Jan/2024	900 nanogram per milliliter	
PROSTATE ANTIGEN TEST	17/May/2024	0 nanogram per milliliter	

Lab Comments :

1) Test Name : PROSTATE ANTIGEN TEST

Lab Comments : Before starting Eligard treatment

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug : Eligard® (Leuprolide acetate)
 Active Substance : 1) Leuprolide acetate
 Drug Characterization : Suspect
 Form Strength : 1) 22.5 Milligram
 Form of Admin : 1) Injection
 Lot Number : 1) Unknown
 Daily Dose : (22.5 milligram(s), 1 in 3 Month)
 Route of Admin : 1) Subcutaneous
 Indications : 1) Prostate cancer [10060862 - Prostate cancer]
 Action(s) Taken With Drug : Unknown

Causality

1) PAIN IN THE SPINE IS CAUSED BY THE PROSTATE CANCER BECAUSE IT METASTASISED IN THE AREA OF THE SPINE (Metastases to spine - 10027468, Metastases to spine - 10027468)

Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable

Continuation Sheet for CIOMS report

- ReChallenge : Not Applicable
- 2) IN THE DAYS PRIOR, HE ALREADY HAD FLU-LIKE SYMPTOMS (Flu - 10016790, Influenza - 10022000)
- Causality as per reporter : Not Reported
- Causality as per Mfr : Not Related
- DeChallenge : Not applicable
- ReChallenge : Not Applicable
- 3) HEADACHE (Headache - 10019211, Headache - 10019211)
- Causality as per reporter : Not Reported
- Causality as per Mfr : Not Related
- DeChallenge : Not applicable
- ReChallenge : Not Applicable
- 4) CHILLS (Chills - 10008531, Chills - 10008531)
- Causality as per reporter : Not Reported
- Causality as per Mfr : Not Related
- DeChallenge : Not applicable
- ReChallenge : Not Applicable
- 5) CAUSES SPASMS (Abdominal spasm - 10051889, Abdominal rigidity - 10000090)
- Causality as per reporter : Not Reported
- Causality as per Mfr : Not Related
- DeChallenge : Not applicable
- ReChallenge : Not Applicable
- 6) HE HAS BEEN EXPERIENCING BURNING IN THE STOMACH, MENTIONING THAT HE CANNOT DIGEST ANYTHING (Dyspepsia - 10013946, Dyspepsia - 10013946)
- Causality as per reporter : Not Reported
- Causality as per Mfr : Not Related
- DeChallenge : Not applicable
- ReChallenge : Not Applicable
- 7) Cessation of therapy by the patient (Therapy cessation by patient - 10072907, Therapy cessation - 10065154)
- Causality as per reporter : Not Reported
- Causality as per Mfr : Not Related
- DeChallenge : Not applicable
- ReChallenge : Not Applicable
- 8) Excessive sweating (Excess sweating - 10015590, Hyperhidrosis - 10020642)
- Causality as per reporter : Not Reported
- Causality as per Mfr : Not Related
- DeChallenge : Not applicable
- ReChallenge : Not Applicable
- 9) Intense hot flashes (Hot flashes - 10020407, Hot flush - 10060800)
- Causality as per reporter : Not Reported
- Causality as per Mfr : Not Related
- DeChallenge : Not applicable
- ReChallenge : Not Applicable
- 10) PAIN IN THE LOWER LIMBS (Pain in limb - 10033447, Pain in extremity - 10033425)
- Causality as per reporter : Not Reported
- Causality as per Mfr : Not Related
- DeChallenge : Not applicable
- ReChallenge : Not Applicable

Labeling :

- 1) PAIN IN THE SPINE IS CAUSED BY THE PROSTATE CANCER BECAUSE IT METASTASISED IN THE AREA OF THE SPINE
CORE Labeled
- 2) IN THE DAYS PRIOR, HE ALREADY HAD FLU-LIKE SYMPTOMS
CORE UnLabeled
- 3) HEADACHE
CORE Labeled
- 4) CHILLS
CORE UnLabeled
- 5) CAUSES SPASMS
CORE UnLabeled
- 6) HE HAS BEEN EXPERIENCING BURNING IN THE STOMACH, MENTIONING THAT HE CANNOT DIGEST ANYTHING
CORE Labeled
- 7) Cessation of therapy by the patient
CORE UnLabeled
- 8) Excessive sweating
CORE Labeled
- 9) Intense hot flashes

Continuation Sheet for CIOMS report

CORE Labeled
 10) PAIN IN THE LOWER LIMBS
 CORE Labeled

2) Drug : Eligard 45 mg (Leuprolide acetate)
 Active Substance : 1) Leuprolide acetate
 Drug Characterization : Suspect
 Form Strength : 1) 45 Milligram
 Form of Admin : 1) Injection
 Lot Number : 1) 14177A1; UNK; UNK
 Daily Dose : (45 milligram(s), 1 in 6 Month)
 Route of Admin : 1) Subcutaneous
 Indications : 1) Prostate cancer [10060862 - Prostate cancer]
 Action(s) Taken With Drug : Unknown

Causality

1) PAIN IN THE SPINE IS CAUSED BY THE PROSTATE CANCER BECAUSE IT METASTASISED IN THE AREA OF THE SPINE (Metastases to spine - 10027468, Metastases to spine - 10027468)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable

2) IN THE DAYS PRIOR, HE ALREADY HAD FLU-LIKE SYMPTOMS (Flu - 10016790, Influenza - 10022000)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable

3) HEADACHE (Headache - 10019211, Headache - 10019211)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable

4) CHILLS (Chills - 10008531, Chills - 10008531)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable

5) CAUSES SPASMS (Abdominal spasm - 10051889, Abdominal rigidity - 10000090)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable

6) HE HAS BEEN EXPERIENCING BURNING IN THE STOMACH, MENTIONING THAT HE CANNOT DIGEST ANYTHING (Dyspepsia - 10013946, Dyspepsia - 10013946)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable

7) Cessation of therapy by the patient (Therapy cessation by patient - 10072907, Therapy cessation - 10065154)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable

8) Excessive sweating (Excess sweating - 10015590, Hyperhidrosis - 10020642)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable

9) Intense hot flashes (Hot flashes - 10020407, Hot flush - 10060800)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable

10) PAIN IN THE LOWER LIMBS (Pain in limb - 10033447, Pain in extremity - 10033425)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related

Continuation Sheet for CIOMS report

DeChallenge : Not applicable
 ReChallenge : Not Applicable

Labeling :

- 1) PAIN IN THE SPINE IS CAUSED BY THE PROSTATE CANCER BECAUSE IT METASTASISED IN THE AREA OF THE SPINE
 CORE Labeled
- 2) IN THE DAYS PRIOR, HE ALREADY HAD FLU-LIKE SYMPTOMS
 CORE UnLabeled
- 3) HEADACHE
 CORE Labeled
- 4) CHILLS
 CORE UnLabeled
- 5) CAUSES SPASMS
 CORE UnLabeled
- 6) HE HAS BEEN EXPERIENCING BURNING IN THE STOMACH, MENTIONING THAT HE CANNOT DIGEST ANYTHING
 CORE Labeled
- 7) Cessation of therapy by the patient
 CORE UnLabeled
- 8) Excessive sweating
 CORE Labeled
- 9) Intense hot flashes
 CORE Labeled
- 10) PAIN IN THE LOWER LIMBS
 CORE Labeled

- 3) Drug : Eligard® Unspecified Device (Leuprolide acetate)
 Active Substance : 1) Leuprolide acetate
 Drug Characterization : Suspect
 Form of Admin : 1) Injection
 Lot Number : 1) Unknown
 Indications : 1) Prostate cancer [10060862 - Prostate cancer]
 Action(s) Taken With Drug : Not applicable

Causality

- 1) PAIN IN THE SPINE IS CAUSED BY THE PROSTATE CANCER BECAUSE IT METASTASISED IN THE AREA OF THE SPINE (Metastases to spine - 10027468, Metastases to spine - 10027468)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable
- 2) IN THE DAYS PRIOR, HE ALREADY HAD FLU-LIKE SYMPTOMS (Flu - 10016790, Influenza - 10022000)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable
- 3) HEADACHE (Headache - 10019211, Headache - 10019211)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable
- 4) CHILLS (Chills - 10008531, Chills - 10008531)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable
- 5) CAUSES SPASMS (Abdominal spasm - 10051889, Abdominal rigidity - 10000090)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable
- 6) HE HAS BEEN EXPERIENCING BURNING IN THE STOMACH, MENTIONING THAT HE CANNOT DIGEST ANYTHING (Dyspepsia - 10013946, Dyspepsia - 10013946)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable
- 7) Cessation of therapy by the patient (Therapy cessation by patient - 10072907, Therapy cessation - 10065154)

Continuation Sheet for CIOMS report

- Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable
- 8) Excessive sweating (Excess sweating - 10015590, Hyperhidrosis - 10020642)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable
- 9) Intense hot flashes (Hot flashes - 10020407, Hot flush - 10060800)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable
- 10) PAIN IN THE LOWER LIMBS (Pain in limb - 10033447, Pain in extremity - 10033425)
 Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable

Labeling :

- 1) PAIN IN THE SPINE IS CAUSED BY THE PROSTATE CANCER BECAUSE IT METASTASISED IN THE AREA OF THE SPINE
CORE
- 2) IN THE DAYS PRIOR, HE ALREADY HAD FLU-LIKE SYMPTOMS
CORE
- 3) HEADACHE
CORE
- 4) CHILLS
CORE
- 5) CAUSES SPASMS
CORE
- 6) HE HAS BEEN EXPERIENCING BURNING IN THE STOMACH, MENTIONING THAT HE CANNOT DIGEST ANYTHING
CORE
- 7) Cessation of therapy by the patient
CORE
- 8) Excessive sweating
CORE
- 9) Intense hot flashes
CORE
- 10) PAIN IN THE LOWER LIMBS
CORE

15. DAILY DOSE(S) (Continuation...)

Dosage Text :

Drug 1 :Eligard®

- 1) 22.5 milligram, q 3 month

22. CONCOMITANT DRUG(S) (Continuation...)

- 1). Drug : Radiotherapy
 Form Strength :
 Indications : 1) Drug use for unknown indication [10057097 - Drug use for unknown indication]
- 2). Drug : BICALUTAMIDE
 Active Substance : 1) BICALUTAMIDE
 Form Strength :
 Form of Admin : 1) Tablet
 Daily Dose : 1) (1 in 1 Day)
 Indications : 1) Prostate cancer [10060862 - Prostate cancer]
 Therapy Dates : 1) From : 19/Mar/2024 To :

23. OTHER RELEVANT HISTORY (Continuation...)

- 2) PROSTATE CANCER (10060862 , Prostate cancer) (Continuing : YES)